Stratos Investment Management LLC Has $1.53 Million Stock Position in McKesson Corporation $MCK

Stratos Investment Management LLC increased its stake in McKesson Corporation (NYSE:MCK) by 53.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,974 shares of the company’s stock after purchasing an additional 690 shares during the quarter. Stratos Investment Management LLC’s holdings in McKesson were worth $1,525,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of McKesson in the 2nd quarter valued at approximately $1,346,661,000. Alliancebernstein L.P. raised its stake in McKesson by 150.4% during the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after purchasing an additional 1,362,386 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of McKesson by 56.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after purchasing an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of McKesson by 45.6% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after buying an additional 261,296 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of McKesson by 68.0% during the second quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock valued at $466,441,000 after buying an additional 257,670 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by company insiders.

McKesson Stock Up 1.8%

MCK stock opened at $951.91 on Thursday. The firm has a 50 day moving average of $835.56 and a two-hundred day moving average of $785.04. McKesson Corporation has a 12 month low of $585.22 and a 12 month high of $971.93. The company has a market capitalization of $116.60 billion, a price-to-earnings ratio of 27.38, a P/E/G ratio of 1.51 and a beta of 0.40.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts expect that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

Wall Street Analysts Forecast Growth

MCK has been the subject of several research analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. Mizuho increased their price target on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Evercore reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of McKesson in a research note on Thursday, November 6th. Finally, Wells Fargo & Company lifted their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $937.07.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.